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Pharmacokinetic Changes and Dosing Modification of
Aminoglycosides in Critically Ill Obese Patients:
A Literature Review
Dimitrios Velissarisa, Vasilios Karamouzosa, Markos Marangosa,
Charalampos Pierrakosb, Menelaos Karanikolasc, d

Abstract
The objective of the paper is to review the literature and provide
recommendations for use of aminoglycoside antibiotics in critically ill obese patients. Literature search in PubMed for all articles
on the use of aminoglycosides in critically ill obese patients was
conducted, and all articles related to pharmacokinetics in obesity
were reviewed. Bibliographies of all searched manuscripts were
also reviewed in an attempt to find additional references. Although
aminoglycoside pharmacokinetics have been described in detail,
data on aminoglycoside use and appropriate dose modification in
critically ill obese patients are very limited. Knowledge on aminoglycoside pharmacokinetics and use in critically ill obese patients
is incomplete. Pathophysiologic changes in obesity can result in
sub- or supra-therapeutic aminoglycoside plasma concentrations,
especially in the presence of sepsis. Rigorous clinical studies are
needed to establish aminoglycoside dosing guidelines in critically
ill obese patients with sepsis.
Keyword: Aminoglycoside; Gentamicin; Amikacin; Tobramycin;
Obesity; Sepsis; Critical illness; Pharmacokinetics

Introduction
Obesity is a major worldwide health problem, and is associated with serious diseases and increased morbidity and mortality. Physiologic changes in obesity significantly influence
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antibiotic pharmacokinetic characteristics, including distribution, protein binding, metabolism and renal excretion. In order
to reach therapeutic levels, some medications require dosing
adjustments in obese patients, especially in the presence of
critical illness. Aminoglycosides act synergistically with other
antimicrobial agents, and are very important for treatment of
serious infections. However, because aminoglycoside plasma
levels can be significantly affected by obesity, due to aminoglycoside distribution into adipose tissue, dosing modification is needed in order to reach therapeutic plasma levels, and
therapeutic drug monitoring (TDM) has been recommended.
The aim of this study is to review data on aminoglycoside
pharmacokinetics in obesity and summarize published data
regarding the use of aminoglycosides and the need for dose
modification in critically ill obese patients with sepsis.

Literature Search Methods
We searched for publications relevant to this review, using
the PubMed database. The initial PubMed search was conducted in September 2012 and was updated in October 2013.
The search was conducted using the terms “aminoglycosides
dosing and obesity”, “aminoglycosides pharmacokinetics
and obesity”, “aminoglycosides in sepsis and obesity” and
“aminoglycosides pharmacokinetics in sepsis” as keywords.
We excluded animal studies, and studies published in languages other than English. There was no exclusion based on
type of aminoglycoside or publication date. The search included all types of articles, including case reports and review
articles, and the bibliography of all extracted manuscripts
was reviewed in attempt to identify additional references. All
articles published in English related to aminoglycoside use
in obesity were reviewed. When we identified publications
of overlapping data, we only used data from the newer or
more detailed publication. Two authors reviewed the abstract
and text of all articles that seemed relevant to this review.

Literature Review
Our literature search revealed 20 articles in the “aminogly-
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Table 1. Summary, in Chronological Order, of Studies on Aminoglycoside Pharmacokinetics and Dose Adjustment
in Obesity

Author, year

Antibiotic studied

Main findings

Schwartz et al,
1978 [1]

Gentamicin, tobramycin

Vd in obese subjects closely approximates Vd in normal subjects
when using the formula: ABW = IBW + 0.4 × (TBW - IBW)

Blouin et al, 1979
[2]

Tobramycin

Tobramycin loading dose based on ABW = IBW + 0.58 × (TBW IBW)

Korsager, 1980 [4]

Gentamicin

Gentamicin uptake in adipose tissue = 43.7% of uptake in total
body mass of normal-weight patients

Bauer et al, 1980
[3]
Bauer et al, 1983
[5]

Amikacin

Amikacin loading dose based on ABW = IBW + 0.38 × (TBW IBW)
Loading dose based on ABW = IBW + 0.4 × (TBW - IBW)

Gentamicin, tobramycin,
amikacin

Leader et al, 1994
[11]

Gentamicin

Initial dose based on calculation of ClCr by Cockroft equation with
IBW + 0.4 × (TBW - IBW)

Traynor et al,
1995 [8]

Tobramycin

The TBW/IBW ratio predicts Vd.
For patients with TBW/IBW ratio ≥ 1.25, doses based on ABW =
IBW + 0.43 × (TBW - IBW)

Wurtz et al, 1997
[10]

Aminoglycosides

DWCF = 0.4, therefore ABW = IBW + 0.4 × (TBW - IBW)

Pai et al, 2007
[12]

Aminoglycosides

Dosing of aminoglycosides should be based on ABW.

ABW: adjusted body weight; ClCr: creatinine clearance; DWCF: dosing weight correction factor; IBW: ideal body weight; TBW: total
body weight; Vd: volume of distribution.

cosides dosing and obesity” term, 42 articles in the “aminoglycosides pharmacokinetics and obesity”, 165 articles in
the “aminoglycosides pharmacokinetics in sepsis” and seven
articles in the “aminoglycosides in sepsis and obesity”. We
then searched for publications with text combining most
keywords. The combination of the above searches revealed
a total of 33 articles, case series and letters which were included in this review.
Overall, we found very limited data on aminoglycoside
pharmacokinetics and dose modification in obesity. Four early studies on morbidly obese patients, by Schwartz referring
to gentamicin and tobramycin in 1978 [1], by Blouin referring to tobramycin in 1979 [2], by Bauer referring to amikacin in 1980 [3] and by Korsager referring to gentamicin in
1980 [4] concluded that morbidly obese patients have larger
volume of distribution (Vd) compared to normal weight patients.
Schwartz et al evaluated the pharmacokinetics of gentamicin and tobramycin and calculated elimination constants
and volumes of distribution in 13 obese vs. 13 normal weight
subjects. Their results showed that gentamicin and tobramycin are distributed less to adipose tissue compared to other
228

tissues, and mean Vd in obese subjects closely approximates
the Vd seen in normal subjects, when using normalized body
mass +40% of adipose mass as total weight in obese subjects
[1]. Bauer at al studied aminoglycoside pharmacokinetics
in two matched groups of 30 normal weight vs. 30 obese
patients with documented Gram negative infection, and concluded that pharmacokinetics are altered in obesity, therefore
morbidly obese patients require significantly higher gentamicin, tobramycin or amikacin doses compared to normal
weight patients [5]. To compensate for increased Vd in obesity, aminoglycoside loading doses can be based on adjusted
body weight (ABW), which is calculated using the formula:
ABW = IBW + 0.4 × (TBW - IBW), where IBW is ideal
body weight, and TBW is total body weight [5]. However,
these studies were conducted at a time when once-daily antibiotic regimens (5 - 7 mg/kg for tobramycin or gentamicin),
which are popular today, were not widely used. Analysis
of pharmacokinetic data from 2073 patients (497 receiving
tobramycin and 1,576 receiving gentamicin) using various
formulas for Vd, showed that Vd was normalized for both
tobramycin and gentamicin at all weight categories with use
of lean body weight (LBW) estimated based as described by
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Janmahasatian et al [6, 7].
In 1995, Traynor et al investigated aminoglycoside pharmacokinetics in 1,708 patients who received gentamicin and
tobramycin. Regression analysis revealed that the TBW to
IBW ratio (TBW/IBW) predicted Vd. Furthermore, there
were no large differences between dosing weight correcting
factors (DWCFs) derived from IBW and body mass index
(BMI)-based classification systems. This study concluded
that, when calculating aminoglycoside doses, BMI values
were not better than IBW, and proposed that DWCF for aminoglycoside doses should be IBW + 0.43 × EBW (where
EBW is the excess body weight (EBW = TBW - IBW)) for
patients with TBW/IBW ratio ≥ 1.25 [8].
In 1997, Wurtz et al published a review on antimicrobial pharmacokinetics and dosing in obesity, and proposed
that, because 30% of adipose tissue is water, a DWCF of
0.3 should be used. Therefore the weight used to calculate
doses of hydrophilic antibiotics is derived from the equation:
IBW + 0.3 × (TBW - IBW), where IBW is derived from the
Devine formula [9] and TBW is total body weight. However,
other clinical data suggest that the DWCF is 0.4 for aminoglycosides [10]. Published data on aminoglycoside DWCFs
are summarized in Table 1 [1-5, 8, 10-12].
Our search revealed several reports describing physiologic changes in obesity [2, 10, 13, 14]. Because aminoglycoside dosing in critically ill obese patients has not been extensively studied, we could only find limited data, including
a literature review by Erstad, which showed that circulatory
changes in sepsis affect dosing and pharmacokinetics [15].
Data published by Cheymol support modification of loading
and maintenance doses in critically ill obese patients due to
physiologic alterations related to sepsis [16]. Although dose
modification is described in studies by Leader, Corcoran and
Blouin, appropriate aminoglycoside doses in critically ill
obese patients are still debated [2, 11, 13, 17].
Regarding existing methods for measuring creatinine
clearance (ClCr), published data provide accurate estimates
for patients with normal weight, but not for obese ones.
Compared to measured ClCr in obese patients, when the
Cockroft-Gault equation is used with IBW, ClCr is underestimated, whereas ClCr is overestimated when TBW is used
[18]. The Salazar-Corcoran equation, which shows strong
correlation between ClCr and fat free body mass is as accurate as the Cockroft-Gault equation for the normal weight
patients, but seems superior when applied to obese patients
[19]. Therefore, when ClCr is not measured, estimation of
ClCr using the Salazar-Corcoran equation should improve
the ability to select appropriate doses for drugs cleared principally by renal filtration.
With regard to administration of aminoglycoside maintenance doses, most meta-analyses showed that once-daily
regimens are equal or superior to multiple dose regimens,
with regard to clinical efficacy, bacteriologic efficacy and
nephrotoxicity [20-24].
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Discussion
Pathophysiologic changes in obesity affect most hydrophilic
medications [10, 14, 25]. Because pharmacokinetic alterations in obesity affect absorption, Vd and clearance of many
antibiotics, estimation of the correct antibiotic dose is of
critical importance, especially in septic patients with multiple organ failure, where morbidity and mortality are high.
However, despite obesity becoming a worldwide problem,
antibiotic dosing in obese patients has not been studied adequately, and published data are very limited [26].
Morbid obesity alters aminoglycosides pharmacokinetics, as both Vd and clearance are increased in morbidly
obese patients compared to patients with normal weight [16],
but most published data in obesity refer to drug distribution.
Pathophysiologic changes in obesity result in altered cardiac
structure and function with increased cardiac output, altered
tissue blood flow and increased gut perfusion. However, drug
absorption does not seem to be altered, and several studies
evaluating drug absorption did not find differences in obese
vs. non-obese patients [10, 15]. At the present time, although
Vd of many drugs, particularly lipophilic ones, is altered in
obesity, there is no universally accepted factor to estimate
Vd in obese individuals [27]. Although plasma proteins such
as a1 acid-glycoprotein and lipoproteins are highly concentrated in obesity, binding of drugs to albumin does not seem
to be altered. Vd of drugs equally soluble in water and oil
(such as aminoglycosides) is slightly increased in obesity.
Also, because distribution of a drug between adipose tissue and other tissues influences pharmacokinetics in obese
patients, loading dose should be adjusted for IBW. Maintenance dosage also needs adjustment, depending on changes
in drug clearance, as described in several studies on obese
individuals [16]. Hepatic clearance of many drugs is also altered in obesity, but the metabolic capacity of the liver must
be reduced > 90% before drug metabolism is significantly
affected [25, 28].
In conclusion, Vd seems to be the pharmacokinetic variable most affected in obesity, and can be estimated using
an ABW that includes a fraction of the excess body weight
(TBW-IBW) [29].
ClCr, a useful measure for approximating glomerular
filtration rate (GFR), is generally overestimated when it is
calculated based on TBW, but is generally underestimated
when based on IBW [2, 10]. The Cockcroft-Gault equation
can be used to estimate GFR in lean patients, but its use in
obesity is questionable due to disparity between muscle mass
and body weight ratio [18]. The Salazar-Corcoran equation
is an attempt to more accurately estimate ClCr in obesity,
by taking into account serum creatinine, gender, TBW, age
and height [19]. A comparison of the Cockroft-Gault vs. the
Salazar-Corcoran equation showed that prediction of gentamicin elimination rate constant, clearance and elimination
half time was best when ClCr was estimated using the Cock-
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roft-Gault equation [11]. However, according to retrospective studies, the Salazar-Corcoran formula is more precise
for obese patients [12, 30].
Aminoglycosides (gentamicin, amikacin, tobramycin,
netilmicin, kanamycin and streptomycin) are cornerstones
of therapy for serious Gram negative and aerobic bacilli
infections [31], therefore appropriate aminoglycoside loading and maintenance dosing is important for good outcome.
When initiating aminoglycoside therapy, a loading dose is
needed to achieve therapeutic levels quickly. The loading
dose is very important with aminoglycosides, because a high
initial dose is needed to maximize their anti-bacterial effect
and lower mortality [32, 33]. In addition, because aminoglycoside effect is concentration-dependent, administration of
maintenance doses using extended interval regimens is preferred. Loading dose depends on Vd and target plasma concentration (Cp), both of which are affected by critical illness:
Vd is altered in sepsis, due to alterations in microvascular
permeability and abnormalities of extracellular body water.
In one prospective study, Vd was estimated to be 0.43 ± 0.12
L/kg in the beginning of gentamicin therapy, but, as patient
condition stabilized Vd was reduced to 0.29 ± 0.17 L/kg on
the seventh day of treatment [34]. Because Vd and drug metabolism change with patient condition, optimization of aminoglycoside dosing is difficult in critical illness: hepatic and
renal failure can affect antibiotic clearance, and critically ill
patients have increased Vd and variable clearance compared
to patients with less severe disease [35]. As Vd increases,
aminoglycoside loading doses need to be increased in sepsis
[15], and plasma level monitoring (also known as TDM) has
been recommended to improve safety and effectiveness [34,
36, 37].
Aminoglycoside dosing in obese critically ill patients is
even more challenging because drug distribution between
fat and lean tissue influences pharmacokinetics, therefore
aminoglycosides, being hydrophilic agents, need dosing adjustment. At the present time, there are limited data on the
effects of fluid changes in critically ill obese ICU patients
with sepsis [15], but the need for dose adjustment has been
established for gentamicin, tobramycin and amikacin [2, 11,
17].
In healthy adults, aminoglycoside Vd is approximately
0.26 L/kg (range: 0.2 - 0.3). However, aminoglycoside dosing needs modification in obesity using a correcting factor
of 0.4, because an estimated 40% of the dose is distributed
into adipose tissue. [11, 15, 17]. Therefore, the equation for
calculating ABW reads as follows: ABW = IBW + 0.4 ×
(TBW - IBW).
The above dosing modification is very important, because calculation of aminoglycoside dosing based on TBW
may result in high serum concentrations, thereby increasing
the risk for nephrotoxicity and ototoxicity [2, 16] in obesity.
However, data regarding nephrotoxicity are conflicting, with
studies on aminoglycoside kinetics showing no significant
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difference between obese patients and patients with normal
weight with regard to ClCr for gentamicin [11].
Obesity is related to glomerular hyperfiltration, rather
than to effects on tubular secretion [7]. The Cockcroft-Gault
[18], the Salazar-Corcoran [19] and the modification of diet
in renal disease (MDRD) [38] equation are the equations
most commonly used for estimation of clearance. However,
although these formulas are widely used, they are not reliable estimators of function, particularly in patients with high
BUN/SCr ratio [39]. Furthermore, the predictive performance of newer formulas such as the MDRD and chronic
kidney disease-epidemiology (CKD-EPI) [40] compared to
the Cockcroft-Gault equation for assessment of kidney function and estimation of aminoglycoside clearance in obesity
is unknown [41]. A study by Pai suggested that the CKDEPI equation best predicts aminoglycoside clearance [7].
Overall, MDRD provides more reliable estimations of renal
function compared to the Cockcroft-Gault formula, but both
formulas lack precision. MDRD is not superior to CockcroftGault for drug dosing, and MDRD estimated GFR (eGFR)
needs adjustment to patient’s body surface area for drug
dosing. Although Cockcroft-Gault has the advantage of simplicity and longer use [42], drug dosing guidelines are often
based on ClCr estimated using the Cockcroft-Gault equation
as surrogate for GFR.
Controversy exists with regard to the use of these formulas in obesity: the Cockcroft-Gault equation relies on
TBW, and therefore overestimates GFR in obese patients.
Similarly, the MDRD equation, which indexes GFR based
on a normalized body surface area of mL/min/1.73 m2 also
overestimates GFR in obese patients.
Aminoglycoside dosing is based on weight, according
to either of two strategies: traditional, more frequent dosing, vs. extended-interval dosing, but dosing interval should
be adjusted in patients with renal impairment. According
to the American Society of Health Systems Pharmacists,
in patients with normal renal function, traditional dosing
consists of 1 - 2 mg/kg doses given multiple times per day,
whereas the newer strategy utilizes 5 - 10 mg/kg every 24
h. Although aminoglycosides have been administered using
multiple daily dosing regimens for decades, newer clinical
and laboratory studies suggest that once-daily dosing confers
advantages with regard to efficacy [43, 44]. With regard to
extended interval dosing in obesity, a retrospective analysis
by Ross suggests that use of DWCF of 40% is accurate [45].
In ICU patients, however, other factors such as sepsis
and renal dysfunction can significantly alter aminoglycoside
pharmacokinetics, and individual TDM is warranted [46].
Details regarding the effects of fluid shifts on aminoglycoside pharmacokinetics have not been well studied in critically ill obese patients. Finally, the advantages of large oncedaily aminoglycoside doses have been questioned, because
of apparent pyrogen-mediated toxicity [47]. As relevant published data are very limited [47], there is great need for well-
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conducted clinical trials on obese critically ill patients [15].
Understanding of the pathophysiologic changes in obesity and knowledge of the literature on aminoglycosides are
valuable for rational determination of dosages in obese patients. As aminoglycosides are first-line drugs in sepsis, there
is clearly a need for more studies on the appropriate use and
dosing of aminoglycosides in critically ill obese patients. It
is important to realize that studies on pharmacokinetics in
obesity have limitations, such as patient population heterogeneity, small patient numbers, the fact that many data are
referring to single doses rather than ongoing use, and limited
knowledge on the effects of obesity on pharmacokinetics.
Failure to appropriately modify doses in obesity can result
in therapeutic failure or increased toxicity, therefore TDM,
when feasible, has been recommended in order to optimize
the safety and effectiveness of aminoglycoside antibiotic
therapy [37, 48].

Conclusion
Modification of drug dosage in obese patients is very important, particularly when using medications with narrow
therapeutic index. Alterations of aminoglycoside pharmacokinetic parameters in obesity may necessitate deviation from
dosages commonly recommended for non-obese individuals,
but knowledge on the influence of obesity on pharmacokinetics is limited. This review shows that currently available
literature supports the need for aminoglycoside dosage modification in critically ill obese patients. Physicians need to
take every possible step to ensure that aminoglycoside doses
are adequate and safe. Because pathophysiologic changes
in obesity can result in sub- or supra-therapeutic concentrations, aminoglycoside doses should be re-evaluated daily in
critically ill obese patients, and TDM can help optimize therapy. Clinicians prescribing antibiotics for critically ill obese
patients should be familiar with drug and patient factors influencing the effectiveness of antibiotic therapy.
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